EUCTR2008-004881-16-FR进行中（未招募）1 期
The Effect of Acadesine on Clinically Significant Adverse Cardiovascular and Cerebrovascular Events in High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by Acadesine in Subjects Undergoing CABG) - RED-CABG Trial
Schering-Plough Research Institute, a Division of Schering Corporation0 个研究点目标入组 7,500 人开始时间: 2009年4月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 7,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •The subject must meet ALL the criteria listed below for entry:
- •1. A subject must be a high-risk patient undergoing non-emergency CABG surgery requiring cardiopulmonary bypass and cardioplegia.
- •2. A subject must be = 50 years of age.
- •3. A subject must have at least one of the following risk factors:
- •a. Female (but not pregnant or lactating), or
- •b. History of prior CABG, or
- •c. History of MI (except for MI within 5 days prior to surgery or MI having
- •occurred more than 2 years previously), or
- •d. History of ischemic stroke, or
- •e. Left ventricular ejection fraction (EF) = 30% (measured any time within
- •the previous 3 months before Screening), or
- •f. Diabetes mellitus requiring insulin and/or antidiabetic agents.
- •4. A subject must have demonstrated on coronary angiography, performed within the past 12 months, to have significant coronary artery stenosis of at least 50% of the left main coronary artery, or 70% or more of three coronary arteries, or 70% or more of two coronary arteries inclusive of the left anterior descending (LAD). The screening coronary angiography must have been performed after any previous PCI or CABG.
- •5. A subject must be willing and able to give Informed Consent.
- •6. A woman of child-bearing potential who is currently sexually active must agree to use a medically accepted method of contraception during screening and for one month after stopping the medication.
- •Medically accepted methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device (IUD), inert or copper-containing IUD, hormone-releasing IUD, systemic hormonal contraceptive, and surgical sterilization (eg, hysterectomy or tubal ligation).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The subject will be excluded from entry if ANY of the criteria listed below are met:
- •1. Subject undergoing planned valve replacement, carotid artery or aortic surgery, distal coronary endarterectomy or ventricular aneurysmectomy, alone or with CABG surgery (repair for mild-to-moderate mitral valve disease with concomitant CABG is not excluded).
- •2. Subject undergoing CABG surgery using intermittent aortic cross clamping without cardioplegia.
- •3. Subject undergoing minimally invasive surgery (ie, without use of cardiopulmonary bypass).
- •4. Subject with an MI within 5 days prior to surgery or greater than 2 years.
- •5. Subject with a pre-operative intra-aortic balloon pump (IABP), left ventricular assist device (LVAD), extra-corporeal membrane oxygenator (ECMO), or other mechanical hemodynamic assist device.
- •6. Subjects with a history or presence of gout or uric acid nephrolithiasis.
- •7. Subjects with a serum creatinine >2 mg/dL (180 umol/L) at Screening.
- •8. Subjects with a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 X Upper Limit of Normal (ULN) at Screening.
- •9. Subject who has received any treatment listed in Table 2 (Prohibited medications for Entry into the Study) in the protocol more recently than the indicated washout period prior to surgery or must continue to receive treatment that is listed in Table 2. (Prohibited medications: 24 hr washout period prior to surgery for adenosine, aminophylline, nicotinic acid, pentoxifylline, theophylline, and cardioplegia solutions containing adenosine, dipyridamole, lidoflazine, or lidocaine; 2 day washout period prior to surgery for dipyridamole; 4 day washout period prior to surgery for allopurinol; 30 day washout period prior to Screening for investigational drugs)
- •10. Administration of food and drinks containing caffeine, theobromines or methylxanthines (such as coffee, tea, colas, some 'energy' drinks or chocolate) is not allowed within 24 hours before surgery.
- •11. Subjects with known allergy/sensitivity to acadesine or its/their excipients.
- •12. Woman who is breast-feeding, pregnant or intends to become pregnant within 30 days of study drug administration.
- •13. Subject who has used any investigational drugs within 30 days of Screening.
- •14. Subject who is participating in any other clinical study.
- •15. Subject who is part of the staff personnel directly involved with this study or who is a family member of the investigational study staff.
- •16. Subject with an inability or unwillingness to abide by the protocol.
研究者
相似试验
进行中（未招募）
1 期
The Effect of Acadesine on Clinically Significant Adverse Cardiovascular and Cerebrovascular Events in High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by Acadesine in Subjects Undergoing CABG) - RED-CABG TrialCoronary artery diseaseMedDRA version: 9.1 Level: LLT Classification code 10011078 Term: Coronary artery diseaseEUCTR2008-004881-16-DESchering-Plough Research Institute, a Division of Schering Corporation7,500
进行中（未招募）
1 期
The Effect of Acadesine on Clinically Significant Adverse Cardiovascular and Cerebrovascular Events in High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass: RED-CABG Trial (Reduction in Cardiovascular Events by Acadesine in Subjects Undergoing CABG). - RED CABG TrialCoronary artery diseaseMedDRA version: 9.1 Level: LLT Classification code 10011078 Term: Coronary artery diseaseEUCTR2008-004881-16-ITSchering-Plough Research Institute, a Division of Schering Corporation7,500
进行中（未招募）
不适用
Does therapy with bosentan tablets have positive effects on the stiffness of the vessels in patients with scleroderma who have ulcers of the fingers of toes?EUCTR2014-002796-28-NLniversity Medical Center Groningen (UMCG)
已完成
4 期
The Clinical Efficacy And Subclinical Effects on arterial STIFFNESS of bosentan therapy added to usual care in patients with systemic sclerosis with digital ulcers.10003816sclerodermaSystemic sclerosisNL-OMON45095niversitair Medisch Centrum Groningen60
已完成
不适用
Investigation of the clinical significances and the pathological features of the lanthanum deposition at the gastric mucosapatients on hemodialysisJPRN-UMIN000038929Osaka medical college42